Encision Reports First Quarter Fiscal Year 2026 Results
Encision Inc. (OTC PINK:ECIA), a medical device company specializing in Active Electrode Monitoring (AEM庐) Technology, reported its fiscal 2026 first quarter results ending June 30, 2025. The company posted total net revenue of $1.6 million, comprising $1.49 million in product revenue and $110,000 in service revenue. The quarter resulted in a net loss of $41,000 ($0.00 per share), compared to a net income of $22,000 in the year-ago quarter.
Key financial metrics include a product gross margin of 55%, down from 58% in the previous year's quarter. Operating expenses totaled $898,239, with significant allocations to sales and marketing ($404,601), general and administrative ($328,198), and research and development ($165,440). The company's cash position decreased to $47,918 from $257,433 at the beginning of the fiscal year.
Encision Inc. (OTC PINK:ECIA), azienda di dispositivi medici specializzata nella tecnologia Active Electrode Monitoring (AEM庐), ha comunicato i risultati del primo trimestre fiscale 2026, chiuso il 30 giugno 2025. La societ脿 ha registrato ricavi netti totali per $1,6 milioni, di cui $1,49 milioni da prodotti e $110.000 da servizi. Il trimestre si 猫 chiuso con una perdita netta di $41.000 (pari a $0,00 per azione), rispetto a un utile netto di $22.000 nello stesso trimestre dell鈥檃nno precedente.
I principali indicatori finanziari mostrano un margine lordo sui prodotti del 55%, in calo rispetto al 58% del trimestre dell鈥檃nno precedente. Le spese operative sono state pari a $898.239, con voci principali dedicate a vendite e marketing ($404.601), amministrazione generale ($328.198) e ricerca e sviluppo ($165.440). La liquidit脿 disponibile 猫 diminuita a $47.918 dai $257.433 all鈥檌nizio dell鈥檈sercizio.
Encision Inc. (OTC PINK:ECIA), compa帽铆a de dispositivos m茅dicos especializada en la tecnolog铆a Active Electrode Monitoring (AEM庐), inform贸 sus resultados del primer trimestre fiscal 2026, finalizado el 30 de junio de 2025. La empresa registr贸 ingresos netos totales de $1,6 millones, compuestos por $1,49 millones en ventas de productos y $110.000 en servicios. El trimestre cerr贸 con una p茅rdida neta de $41.000 ($0,00 por acci贸n), frente a un beneficio neto de $22.000 en el mismo trimestre del a帽o anterior.
Entre los indicadores clave, el margen bruto de productos fue del 55%, frente al 58% del trimestre anterior. Los gastos operativos sumaron $898.239, con partidas principales en ventas y marketing ($404.601), administraci贸n general ($328.198) e investigaci贸n y desarrollo ($165.440). La posici贸n de efectivo se redujo a $47.918 desde $257.433 al inicio del ejercicio.
Encision Inc. (OTC PINK:ECIA)電� 鞎№嫲敫� 鞚茧爥韸鸽霌� 氇媹韯半(AEM庐) 旮办垹鞚� 鞝勲鞙茧 頃橂姅 鞚橂旮瓣赴 須岇偓搿�, 2025雲� 6鞗� 30鞚茧 膦呺霅� 2026 須岅硠鞐半弰 1攵勱赴 鞁れ爜鞚� 氚滍憸頄堨姷雼堧嫟. 須岇偓鞚� 齑� 靾滊Г於滌潃 $1.6氚彪鞙茧, 鞝滍拡 毵れ稖 $1.49氚彪瓿� 靹滊箘鞀� 毵れ稖 $110,000搿� 甑劚霅橃棃鞀惦媹雼�. 頃措嫻 攵勱赴電� 靾滌啇鞁� $41,000(欤茧嫻 $0.00)鞚� 旮半頄堨溂氅�, 鞝勲厔 霃欔赴鞐愲姅 靾滌澊鞚� $22,000毳� 旮半頄堨姷雼堧嫟.
欤检殧 鞛 歆�響滊電� 鞝滍拡 毵れ稖齑濎澊鞚惦 55%搿� 鞝勲厔 霃欔赴 58%鞐愳劀 頃橂澖頄堨姷雼堧嫟. 鞓侅梾牍勳毄鞚� 齑� $898,239搿� 歆戧硠霅愳溂氅�, 韺愲Г 氚� 毵堨紑韺�($404,601), 鞚茧皹甏�毽�($328,198), 鞐瓣惮臧滊皽($165,440)鞐� 欤茧 氚半秳霅橃棃鞀惦媹雼�. 順勱笀 氤挫湢鞎§潃 須岅硠鞐半弰 鞁滌瀾 鞁滌爯鞚� $257,433鞐愳劀 $47,918搿� 臧愳唽頄堨姷雼堧嫟.
Encision Inc. (OTC PINK:ECIA), soci茅t茅 de dispositifs m茅dicaux sp茅cialis茅e dans la technologie Active Electrode Monitoring (AEM庐), a publi茅 ses r茅sultats du premier trimestre fiscal 2026, clos le 30 juin 2025. La soci茅t茅 a affich茅 un chiffre d'affaires net total de 1,6 M$, comprenant 1,49 M$ de ventes de produits et 110 000 $ de services. Le trimestre s'est sold茅 par une perte nette de 41 000 $ (0,00 $ par action), contre un b茅n茅fice net de 22 000 $ au m锚me trimestre de l'ann茅e pr茅c茅dente.
Parmi les indicateurs cl茅s, la
Encision Inc. (OTC PINK:ECIA), ein Medizinprodukteunternehmen, das auf Active Electrode Monitoring (AEM庐) Technologie spezialisiert ist, berichtete 眉ber seine Ergebnisse des ersten Quartals des Gesch盲ftsjahres 2026 zum 30. Juni 2025. Das Unternehmen erzielte gesamte Nettoums盲tze von $1,6 Mio., davon $1,49 Mio. Produktumsatz und $110.000 Serviceumsatz. Das Quartal schloss mit einem Nettoverlust von $41.000 (je Aktie $0,00), nach einem Nettogewinn von $22.000 im Vorjahresquartal.
Wesentliche Finanzkennzahlen zeigen eine Produkt-Bruttomarge von 55%, gegen眉ber 58% im Vorjahresquartal. Die Betriebsausgaben beliefen sich auf $898.239, mit wesentlichen Anteilen f眉r Vertrieb und Marketing ($404.601), allgemeine Verwaltung ($328.198) sowie Forschung und Entwicklung ($165.440). Die Liquidit盲tsposition sank von $257.433 zu Beginn des Gesch盲ftsjahres auf $47.918.
- Service revenue increased significantly to $109,896 from $38,971 year-over-year
- Reduction in operating expenses to $898,239 from $914,320 in the previous year
- Accounts receivable improved by $37,046 during the quarter
- Net loss of $41,133 compared to net income of $22,041 in the year-ago quarter
- Product revenue declined to $1.49 million from $1.59 million year-over-year
- Gross margin decreased to 55% from 58% in the previous year
- Cash position significantly decreased to $47,918 from $257,433
- Interest expense increased to $18,009 from $6,369 year-over-year
BOULDER, CO / / August 15, 2025 / Encision Inc. (OTC PINK:ECIA), a medical device company owning patented Active Electrode Monitoring (AEM庐) Technology that prevents dangerous radiant energy burns in minimally invasive surgery, today announced financial results for its fiscal 2025 first quarter that ended June 30, 2025.
The Company posted quarterly product net revenue of
Encision Inc. designs and markets a portfolio of high-performance surgical instrumentation that delivers advances in patient safety with AEM technology, surgical performance, and value to hospitals across a broad range of minimally invasive surgical procedures. Based in Boulder, Colorado, the company pioneered the development and deployment of Active Electrode Monitoring, AEM technology, to eliminate dangerous stray energy burns during minimally invasive procedures. For additional information about all our products, please visit .
In accordance with the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, the Company notes that statements in this press release and elsewhere that look forward in time, which include everything other than historical information, involve risks and uncertainties that may cause actual results to differ materially from those indicated by the forward-looking statements. Factors that could cause the Company's actual results to differ materially include, among others, its ability to develop new or enhanced products and have such products accepted in the market, its ability to increase net sales through the Company's distribution channels, its ability to compete successfully against other manufacturers of surgical instruments, insufficient quantity of new account conversions, insufficient cash to fund operations, delay in developing new products and receiving FDA approval for such new products and other factors discussed in the Company's filings with the Securities and Exchange Commission. Readers are encouraged to review the risk factors and other disclosures appearing in the Company's Annual Report on Form 10-K for the year ended March 31, 2024 and subsequent filings with the Securities and Exchange Commission. We do not undertake any obligation to update publicly any forward-looking statements, whether as a result of the receipt of new information, future events, or otherwise.
CONTACT: Brandon Shepard , Encision Inc., 303-444-2600, [email protected]
Encision Inc.
Condensed Balance Sheets
June 30, 2025 | March 31, 2025 | |||||||
Unaudited | Audited | |||||||
ASSETS | ||||||||
Current assets: | ||||||||
Cash | $ | 47,918 | $ | 257,433 | ||||
Accounts receivable | 749,426 | 786,471 | ||||||
Inventories | 1,534,887 | 1,483,182 | ||||||
Prepaid expenses | 118,308 | 85,679 | ||||||
Total current assets | 2,450,539 | 2,612,765 | ||||||
Equipment: | ||||||||
Furniture, fixtures, and equipment, at cost | 2,591,981 | 2,585,446 | ||||||
Accumulated depreciation | (2,358,134 | ) | (2,340,689 | ) | ||||
Equipment, net | 233,847 | 244,757 | ||||||
Right of use asset, net | 1,199,806 | 568,395 | ||||||
Patents, net | 166,708 | 171,890 | ||||||
Other assets | 80,655 | 72,892 | ||||||
TOTAL ASSETS | 4,131,555 | 3,670,699 | ||||||
LIABILITIES AND SHAREHOLDERS' EQUITY | ||||||||
Current liabilities: | ||||||||
Accounts payable | $ | 328,123 | $ | 346,900 | ||||
Line of credit | 320,440 | 395,964 | ||||||
Secured notes | 39,802 | 44,128 | ||||||
Accrued compensation | 208,850 | 180,850 | ||||||
Deferred Revenue | 2,574 | 17,401 | ||||||
Other accrued liabilities | 129,615 | 160,274 | ||||||
Accrued lease liability | 248,469 | 430,398 | ||||||
Total current liabilities | 1,277,873 | 1,575,915 | ||||||
Long-term liability: | ||||||||
Secured notes | 169,997 | 177,470 | ||||||
Accrued lease liability | 1,061,597 | 266,212 | ||||||
Total liabilities | 2,509,467 | 2,019,597 | ||||||
Commitments and contingencies (Note 4) | ||||||||
Shareholders' equity: | ||||||||
Preferred stock, no par value: 10,000,000 shares authorized; none issued and outstanding | - | - | ||||||
Common stock and additional paid-in capital, no par value: 100,000,000 shares authorized; 11,879,645 and 11,879,645 issued and outstanding at June 30, 2025, and March 31, 2025, respectively | 24,428,466 | 24,416,347 | ||||||
Accumulated (deficit) | (22,806,378 | ) | (22,765,245 | ) | ||||
Total shareholders' equity | 1,622,088 | 1,651,102 | ||||||
TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY | $ | 4,131,555 | $ | 3,670,699 | ||||
Encision Inc.
Condensed Statements of Operations
(Unaudited)
Three Months Ended | ||||||||
June 30, 2025 | June 30, 2024 | |||||||
NET REVENUE: | ||||||||
Product | $ | 1,492,832 | $ | 1,591,960 | ||||
Service | 109,896 | 38,971 | ||||||
Total revenue | 1,602,728 | 1,630,931 | ||||||
COST OF REVENUE: | ||||||||
Product | 666,811 | 667,635 | ||||||
Service | 57,458 | 20,633 | ||||||
Total cost of revenue | 724,269 | 688,268 | ||||||
GROSS PROFIT | 878,459 | 942,663 | ||||||
OPERATING EXPENSES: | ||||||||
Sales and marketing | 404,601 | 423,237 | ||||||
General and administrative | 328,198 | 351,903 | ||||||
Research and development | 165,440 | 139,180 | ||||||
Total operating expenses | 898,239 | 914,320 | ||||||
OPERATING (LOSS) INCOME | (19,780 | ) | 28,343 | |||||
Interest expense, net | (18,009 | ) | (6,369 | ) | ||||
Other (expense) income, net | (3,344 | ) | 67 | |||||
Interest expense and other (expense), income, net | (21,353 | ) | (6,302 | ) | ||||
(LOSS) INCOME BEFORE PROVISION FOR INCOME TAXES | (41,133 | ) | 22,041 | |||||
Provision for income taxes | - | - | ||||||
NET (LOSS) INCOME | $ | (41,133 | ) | $ | 22,041 | |||
Net (loss) income per share-basic and diluted | $ | (0.00 | ) | $ | (0.00 | ) | ||
Weighted average shares-basic | 11,879,645 | 11,879,145 | ||||||
Weighted average shares-diluted | 11,879,645 | 11,906,918 | ||||||
Encision Inc.
Condensed Statements of Cash Flows
(Unaudited)
Three Months Ended | June 30, 2025 | June 30, 2024 | ||||||
Cash flows (used in) operating activities: | ||||||||
Net (loss) income | $ | (41,133 | ) | $ | 22,041 | |||
Adjustments to reconcile net (loss) income to net cash (used in) provided by operating activities: | ||||||||
Depreciation and amortization | 22,777 | 19,322 | ||||||
Stock-based compensation expense | 12,119 | 12,374 | ||||||
Provision for inventory obsolescence, net change | 3,982 | 1,090 | ||||||
Change in operating assets and liabilities: | ||||||||
Right of use asset, net | (17,955 | ) | (3,456 | ) | ||||
Accounts receivable | 37,046 | 74,980 | ||||||
Inventories | (55,687 | ) | 83,125 | |||||
Prepaid expenses and other assets | (40,393 | ) | (21,587 | ) | ||||
Accounts payable | (33,605 | ) | (76,123 | ) | ||||
Accrued compensation and other accrued liabilities | (2,659 | ) | 5,762 | |||||
Net cash provided by (used in) provided by operating activities | (115,508 | ) | 117,528 | |||||
Cash flows (used in) investing activities: | ||||||||
Acquisition of property and equipment | (6,535 | ) | (14,144 | ) | ||||
Patent costs | (150 | ) | (5,397 | ) | ||||
Net cash (used in) investing activities | (6,685 | ) | (19,541 | ) | ||||
Cash flows from financing activities: | ||||||||
(Payments) to borrowing from line of credit | (75,524 | ) | 142,736 | |||||
(Payments) from options exercised | - | (1,449 | ) | |||||
(Paydown) Secured notes | (11,798 | ) | (11,339 | ) | ||||
Net cash (used in) provided by financing activities | (87,322 | ) | 129,948 | |||||
Net (decrease) increase in cash | (209,515 | ) | 227,935 | |||||
Cash, beginning of fiscal year | 257,433 | 42,509 | ||||||
Cash, end of fiscal quarter | 47,918 | 270,444 | ||||||
Supplemental disclosures of cash flow information: | ||||||||
Cash paid during the period for interest | $ | 18,009 | $ | 6,369 | ||||
SOURCE: Encision, Inc.
View the original on ACCESS Newswire
FAQ
What were Encision's (ECIA) Q1 2026 earnings results?
How did ECIA's product revenue perform in Q1 2026 compared to last year?
What is Encision's current cash position as of Q1 2026?
How much did ECIA spend on R&D in Q1 2026?
What is Encision's main product technology?
